Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)

Drug Alias NameBCMA CAR-T cells (Chongqing Precision Biotech Co Ltd)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple MyelomaLymphoma, B-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesChongqing Precision Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesChongqing Precision Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A